Navigation Links
Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care

FARMINGDALE, N.Y., May 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance at the 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS), which was held in Dallas, TX, April 26-29, 2009, and is widely regarded as the premier educational wound care-focused program in the United States. Also, the SAWC/WHS symposium is the official meeting of the Association for the Advancement of Wound Care (AAWC), a pre-eminent multi-disciplinary organization for wound care. Misonix exhibited and demonstrated its SonicOne(R) Ultrasonic Wound Cleansing and Debridement System to many of the approximately 2,300 clinicians in attendance.

As part of the therapeutic educational program, Oscar Alvarez, Ph.D., FAPWCA, Director of the Center for Curative and Palliative Wound Care at Calvary Hospital, Bronx, NY, and an Associate Professor of Medicine at New York Medical College, presented data on the use of the SonicOne for wound debridement compared to standard "sharps" debridement. Dr. Alvarez's data, for more than 75 patients, with about half of the patients receiving SonicOne treatment and the other half receiving "sharps" treatment, demonstrated statistically significant reductions in the time to healing and the number of debridement procedures when SonicOne was selected as the method of choice.

From humble beginnings in 1988, when a small group of nurses and physicians interested in this emerging discipline created a mission and vision to provide an interdisciplinary forum on wound care, the SAWC/WHS has grown, becoming the largest annual gathering of wound care clinicians in the United States. The SAWC/WHS partnership reflects the need for clinicians to better understand the research and science behind wound management in pursuit of optimal patient outcomes.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased to demonstrate its commitment to the large and rapidly growing wound care market by supporting important educational programs like SAWC/WHS and ASWC," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The wound care product platform, we believe, can make an important contribution to improving patient outcomes and we are gratified when data is presented by clinical experts that support our investment in wound care Research and Development."

About Misonix:

Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Participation in Annual Diabetic Foot Global Conference
2. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
3. Misonix Announces New HIFU Distribution Agreement For Portugal
4. Misonix Announces New HIFU Distribution Agreement for Romania and Bulgaria
5. Misonix Announces New Distribution Agreement for Portugal
6. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
7. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
8. Misonix Announces New Sales Agency Agreement for Eastern Europe
9. Misonix Announces New Distribution Agreement for Israel
10. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
11. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
Post Your Comments:
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds to ... that the first impression be positive and reflects business values. If a client starts ... or want to return. They will also share their thoughts about a business with ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, ... at a live taping of the next CURE Connections® video series ... Cancers 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding ... an innovative study designed to yield insights into how to detect and treat pancreatic ... for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present ...
(Date:11/24/2015)... ... 24, 2015 , ... Sir Grout of Baltimore is proud ... The award recognizes good companies for excellence in service and a commitment to ... hard surface restoration company earned this recognition after a thorough review by the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
(Date:11/24/2015)... , UAE, November 24, 2015   ... and dietician deliver s advice and ...   More than 50% of ... to keep themselves healthy according to the DHA   femMED ... in the UAE    Dubai residents are not ...
(Date:11/24/2015)... , Nov. 24, 2015  Eyewear brand Revo ... collaboration with U2 lead singer and activist Bono as part ... prevent vision impairment and blindness in more than 5 million ... Revo will donate $10 from the sale of every ... up to a total of $10 million to the "Buy ...
Breaking Medicine Technology: